ACT ESCITALOPRAM ODT DIN 02454300
Health Canada record
| Active ingredient(s) | ESCITALOPRAM 20 MG |
|---|---|
| Dosage form | Tablet (Orally-Disintegrating) |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N06AB10 ESCITALOPRAM |
| Original market date | 17-Aug-2016 |
| Current status date | 01-May-2020 |
| Source | Health Canada DPD |
Establishment licence of the holder
Teva Canada Limited — licence 101810, currently licensed, last inspection rating C (2025-03-04).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ESCITALOPRAM
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02454297 | ACT ESCITALOPRAM ODT | TEVA CANADA LIMITED | Tablet (Orally-Disintegrating) | ESCITALOPRAM 10 MG | Marketed |
| 02391449 | CIPRALEX MELTZ | LUNDBECK CANADA INC | Tablet (Orally-Disintegrating) | ESCITALOPRAM 10 MG | Cancelled Post Market |
| 02391457 | CIPRALEX MELTZ | LUNDBECK CANADA INC | Tablet (Orally-Disintegrating) | ESCITALOPRAM 20 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 23538 | 2020-05-01 | Abbreviated New Drug Submission (ANDS) | MERGER-BUYOUT |
| 18069 | 2016-05-03 | Abbreviated New Drug Submission (ANDS) |
International API supply for ESCITALOPRAM
27 active FDA Drug Master Files.
Request a quote for ACT ESCITALOPRAM ODT